s6y

6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filed
Period
Accession number
0001213900-26-107425

Documents

  1. REPORT OF FOREIGN PRIVATE ISSUER 6-K
  2. PRESS RELEASE TITLED: "CLEARMIND ADVANCES DIALOGUE WITH U.S. FEDERAL GOVERNMENT ON PSYCHEDELIC THERAPIES, SUBMITTING RECOMMENDATIONS TO FDA" EX-99.1

On sec.gov